Vertex Pharmaceuticals stock gains EUR 485.85, up 0.65%
Published on 11/18/2026 at 08:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey dates and business drivers
- Vertex reported third-quarter 2026 revenue of USD 3.44 billion, up 12 percent year over year.
- The company lifted its full-year 2026 revenue guidance to USD 13.15 billion to USD 13.25 billion.
- The FDA has set November 30, 2026, as the target action date for povetacicept in IgA nephropathy.
Vertex Pharmaceuticals stock traded at EUR 485.85 on Lang & Schwarz at 08:42 CET on Wednesday, November 18, 2026, 0.65 percent above the Xetra close of Tuesday, November 17, 2026.
Vertex Pharmaceuticals develops medicines for serious diseases, with cystic fibrosis therapies forming the core of its commercial business alongside newer products in pain, sickle cell disease and other areas.
The company's third-quarter 2026 revenue rose 12 percent to USD 3.44 billion, and management raised full-year revenue guidance to USD 13.15 billion to USD 13.25 billion. The Financial Times Markets reported that the FDA assigned November 30, 2026, as the target action date for povetacicept in IgA nephropathy.
US investors will also track the S&P 500 as the broader market backdrop.
